Guillermo E. Umpierrez, M.D., Roma Gianchandani, M.D., Dawn Smiley, M.D., Sol Jacobs, M.D., David H. Wesorick, M.D., Christopher Newton, M.D., Farnoosh Farrokhi, M.D., Limin Peng, P.H.D. David Reyes, M.D., Sangeeta Lathkar-Pradhan, M.B.B.S., Francisco

1
Guillermo E. Umpierrez, M.D., Roma Gianchandani,
M.D., Dawn Smiley, M.D., Sol Jacobs, M.D., David
H. Wesorick, M.D., Christopher Newton, M.D.,
Farnoosh Farrokhi, M.D., Limin Peng, P.H.D. David
Reyes, M.D., Sangeeta Lathkar-Pradhan, M.B.B.S.,
Francisco Pasquel, M.D.
Diabetes Care Volume 36 3430-3435 November, 2013
2
STUDY OBJECTIVE  

• To investigate the safety and efficacy of
  sitagliptin (Januvia) for inpatient management of
  type 2 diabetes (T2D) in general medicine and
  surgery patients

Umpierrez G. E. et al. Diabetes Care
2013363430-3435
3
STUDY DESIGN AND METHODS

• T2D patients were randomized to receive
  sitagliptin alone or in combination with glargine
  insulin (glargine) or to a basal bolus insulin
  regimen (glargine and lispro) plus supplemental
  (correction) doses of lispro
• Major study outcomes
• Differences in daily blood glucose (BG)
• Frequency of treatment failures (defined as
  three or more consecutive BG gt240 mg/dL or a mean
  daily BG gt240 mg/dL)
• Hypoglycemia between groups

Umpierrez G. E. et al. Diabetes Care
2013363430-3435
4
RESULTS

• Glycemic control improved similarly in all
  treatment groups
• There were no differences in
• Mean daily BG after the first day of treatment
• Number of readings within a BG target of 70 and
  140 mg/dL
• Number of BG readings gt200 mg/dL
• Number of treatment failures
• Total daily insulin dose and number of insulin
  injections were significantly less in the
  sitagliptin groups compared with the basal bolus
  group
• There were no differences in length of hospital
  stay or in the number of hypoglycemic events
  between groups

Umpierrez G. E. et al. Diabetes Care
2013363430-3435
5
Umpierrez G. E. et al. Diabetes Care
2013363430-3435
6
Umpierrez G. E. et al. Diabetes Care
2013363430-3435
7
Umpierrez G. E. et al. Diabetes Care
2013363430-3435
8
CONCLUSIONS

• Treatment with sitagliptin alone or in
  combination with basal insulin is safe and
  effective for the management of hyperglycemia in
  general medicine and surgery patients with T2D

Umpierrez G. E. et al. Diabetes Care
2013363430-3435
9
Umpierrez G. E. et al. Diabetes Care
2013363430-3435